These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9406730)

  • 1. Recurrence of Hodgkin's disease after indium-111 and yttrium-90 labeled antiferritin administration.
    Vriesendorp HM; Quadri SM; Andersson BS; Wyllie CT; Dicke KA
    Cancer; 1997 Dec; 80(12 Suppl):2721-7. PubMed ID: 9406730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment.
    Herpst JM; Klein JL; Leichner PK; Quadri SM; Vriesendorp HM
    J Clin Oncol; 1995 Sep; 13(9):2394-400. PubMed ID: 7666099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01.
    Vriesendorp HM; Herpst JM; Germack MA; Klein JL; Leichner PK; Loudenslager DM; Order SE
    J Clin Oncol; 1991 Jun; 9(6):918-28. PubMed ID: 2033428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabeled immunoglobulin therapy in patients with Hodgkin's disease.
    Vriesendorp HM; Quadri SM
    Cancer Biother Radiopharm; 2000 Oct; 15(5):431-45. PubMed ID: 11155816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease.
    Vriesendorp HM; Morton JD; Quadri SM
    Cancer Res; 1995 Dec; 55(23 Suppl):5888s-5892s. PubMed ID: 7493365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of radiolabeled polyclonal antiferritin in patients with Hodgkin's disease.
    Lai J; Quadri SM; Borchardt PE; Harris L; Wucher R; Askew E; Schweichel L; Vriesendorp HM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3315s-3323s. PubMed ID: 10541380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody.
    Decaudin D; Levy R; Lokiec F; Morschhauser F; Djeridane M; Kadouche J; Pecking A
    Anticancer Drugs; 2007 Jul; 18(6):725-31. PubMed ID: 17762404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyclonal 90Yttrium labeled antiferritin for refractory Hodgkin's disease.
    Vriesendorp HM; Herpst JM; Leichner PK; Klein JL; Order SE
    Int J Radiat Oncol Biol Phys; 1989 Oct; 17(4):815-21. PubMed ID: 2674084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of reagents for human radioimmunotherapy.
    Vriesendorp HM; Quadri SM; Stinson RL; Onyekwere OC; Shao Y; Klein JL; Leichner PK; Williams JR
    Int J Radiat Oncol Biol Phys; 1992; 22(1):37-45. PubMed ID: 1727128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease.
    Vriesendorp HM; Quadri SM; Wyllie CT; Lai J; Borchardt PE; Harris L; Wucher R; Askew E; Schweichler L
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3324s-3329s. PubMed ID: 10541381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease.
    Bierman PJ; Vose JM; Leichner PK; Quadri SM; Armitage JO; Klein JL; Abrams RA; Dicke KA; Vriesendorp HM
    J Clin Oncol; 1993 Apr; 11(4):698-703. PubMed ID: 8478663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The theoretical implications and experimental and clinical results of radiolabeled antiferritin.
    Order SE
    Acta Oncol; 1990; 29(6):689-94. PubMed ID: 2223137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proposal for translational analysis and development of clinical radiolabeled immunoglobulin therapy.
    Vriesendorp HM; Quadri SM; Jaeckle KA; Freedman RS; Cromeens DM
    Radiother Oncol; 1996 Nov; 41(2):151-61. PubMed ID: 9004359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetry and treatment planning for 90Y-labeled antiferritin in hepatoma.
    Leichner PK; Yang NC; Frenkel TL; Loudenslager DM; Hawkins WG; Klein JL; Order SE
    Int J Radiat Oncol Biol Phys; 1988 May; 14(5):1033-42. PubMed ID: 2834309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma.
    Klein JL; Nguyen TH; Laroque P; Kopher KA; Williams JR; Wessels BW; Dillehay LE; Frincke J; Order SE; Leichner PK
    Cancer Res; 1989 Nov; 49(22):6383-9. PubMed ID: 2553255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
    Schnell R; Dietlein M; Schomäcker K; Kobe C; Borchmann P; Schicha H; Hallek M; Engert A
    Onkologie; 2008 Feb; 31(1-2):49-51. PubMed ID: 18268399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ
    J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
    Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
    J Nucl Med; 1998 Mar; 39(3):476-84. PubMed ID: 9529295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy.
    Gokhale AS; Mayadev J; Pohlman B; Macklis RM
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):194-201. PubMed ID: 16111589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.